Welcome to our online store!

More Views

Solu-medrol powder for solution for injection 1000 mg, complete with solvent, 15.6 ml, in vials 1 pcs. Солу-медрол

Product sku: MD3451

Availability: In stock

Only 54 left


Quick Overview

Corticosteroids for systemic use. Glucocorticoids



Solu-Medrol Indications

Anti-inflammatory treatment.
· Rheumatic diseases.

As adjunctive therapy for short-term use (to help the patient survive an acute episode or exacerbation) in the following diseases:

- post-traumatic osteoarthritis;

- synovitis in osteoarthritis;

- rheumatoid arthritis, in particular juvenile rheumatoid arthritis (in some cases there may be a need for low-dose maintenance therapy);

- acute and subacute bursitis;

- epicondylitis;

- acute nonspecific tendosynovitis;

- acute gouty arthritis;

- psoriatic arthritis;

- ankylosing spondylitis.

· Collagenosis (systemic connective tissue disease).

During exacerbation or as maintenance therapy in some cases with diseases such as:

- systemic lupus erythematosus (and lupus nephritis);

- acute rheumatic carditis;

- systemic dermatomyositis (polymyositis);

- nodular periarteritis;

- Goodpasture's syndrome.

· Dermatological diseases:

- vesicles;

- severe erythema multiforme (Stevens-Johnson syndrome);

- exfoliative dermatitis;

- bullous herpetiform dermatitis;

- severe seborrheic dermatitis;

- severe psoriasis;

- fungal mycosis;

- urticaria

· Allergic conditions.

Control of severe or debilitating allergic conditions that do not respond to proper traditional treatment, in diseases such as:

- bronchial asthma;

- contact dermatitis;

- atopic dermatitis;

- serum sickness;

- seasonal or perennial allergic rhinitis;

- hypersensitivity reactions to drugs;

- urticaria

- acute non-infectious laryngeal edema (the drug of first choice is epinephrine).

· Ophthalmic diseases.

Severe acute and chronic allergic and inflammatory processes in the eye, in particular:

- ocular form of Herpes zoster;

- iritis, iridocyclitis;

- chorioretinitis;

- diffuse posterior uveitis and choroiditis;

- optic neuritis;

- sympathetic ophthalmia;

- inflammation of the middle segment of the eye;

- allergic conjunctivitis;

- allergic ulcers of the cornea;

- keratitis.

· Diseases of the gastrointestinal tract.

Critical periods for the following diseases:

- ulcerative colitis (systemic therapy);

- regional enteritis (systemic therapy).

· Respiratory diseases:

- sarcoidosis of the lungs;

- beryllium;

- fulminant or disseminated pulmonary tuberculosis, when used concomitantly with appropriate anti-tuberculosis chemotherapy;

- Lefler's syndrome, which cannot be treated by other means;

- aspiration pneumonitis;

- moderate and severe pneumonia caused by Pneumocystis carinii in AIDS patients (as adjunctive therapy during the first 72 hours of antipneumocystis therapy);

- exacerbation of chronic obstructive pulmonary disease.

· Conditions that are accompanied by edema.

For induction of diuresis or remission in proteinuria in nephrotic syndrome, proteinuria without uremia.


Systemic fungal infections.

Hypersensitivity to methylprednisolone or to any of the excipients listed in Composition.

Solu-Medrol 40 mg is contraindicated in patients with known or suspected cow's milk allergy (see section 4.4).

Relative contraindications.

Special risk groups. Patients in the following special risk groups should be closely monitored and treated as soon as possible (see also sections “Special warnings and special precautions for use” and “Adverse reactions”): children, patients with diabetes mellitus, hypertension , a history of psychiatric symptoms, certain infectious diseases, in particular tuberculosis or certain viral diseases, such as herpes or shingles, accompanied by symptoms in the eye.

Dosage & Administration

Methylprednisolone sodium succinate solution can be administered by intravenous or intramuscular injection or by intravenous infusion. When providing primary care, preference is given to intravenous injection (see Table 1 for information on recommended doses). The dose for infants and children can be reduced, but should be guided more by the severity of the condition and the patient's response to treatment, rather than his age or body weight. The dose should be at least 0.5 mg / kg body weight every 24 hours.

In adult idiopathic thrombocytopenic purpura, the drug is used only intravenously (intramuscular use is contraindicated).

Product Tags

Use spaces to separate tags. Use single quotes (') for phrases.